The Company is recruiting a new CEO for its next stage of growth – Dr. Toleikis, President and CEO, to transition to Chief Technology Officer upon new appointment LONDON, ON… Read More
Late-Breaking TROPiCS-02 Analysis Shows that Trodelvy Demonstrates Consistent Efficacy Across Trop-2 Expression Levels Trop-2 is Highly Expressed in 90% of Breast Cancers Trodelvy is Currently Under Priority Review with the… Read More
Sustainable alternative to squalene extracted from shark liver oil Adjuvant component for parenteral drug delivery applications Increases share of next-generation solutions at Evonik ESSEN, DE — Evonik has launched a… Read More
The nasal photodisinfection study met the primary endpoint. Staphylococcus aureus (S. aureus) was eliminated or significantly decreased in 86% of carriers (p<0.001) in the trial. The study also met the secondary endpoint. Analysis of… Read More
VANCOUVER, BC — Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that the United… Read More
